Safeguarding Advanced Therapies—The Dangers of Therapeutic Neuroabandonment: How Should We Ensure Patient Safety and Scientific Integrity When a Commercial Clinical Trial Sponsor Becomes Insolvent? | Synapse
May 31, 2026
Safeguarding Advanced Therapies—The Dangers of Therapeutic Neuroabandonment: How Should We Ensure Patient Safety and Scientific Integrity When a Commercial Clinical Trial Sponsor Becomes Insolvent?
Key Points
This work explores the implications of therapeutic neuroabandonment when trial sponsors face financial failure.
Qualitative analysis of existing literature regarding clinical trial sponsor insolvency.
Evaluation of ethical and safety concerns in the context of patient care.
Identifies gaps in patient protection during sponsor insolvency.
Discusses potential regulatory measures to safeguard scientific integrity.
Abstract
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.